SQZ AAC HPV
Alternative Names: SQZ AAC HPVLatest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator SQZ Biotech
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (Parenteral)
- 03 Nov 2023 Efficacy and adverse events data from the phase I ENVOY-001 trial in Solid tumour released by SQZ Biotech